Invasive Lobular Carcinoma: Kristie's Survivor Story

Patient Info: Kristie, Female

As of August 2024, Kristie was focused on survivorship and advocacy after extensive ILC treatment that included 20 weeks of chemotherapy, 25 radiation treatments, 2 years on Verzenio, estrogen blockers, and 5 surgeries.

Lobular Breast Cancer AllianceRead more →

Breast Cancer: Krista's Patient Story

Patient Info: Krista Brown, Female

Biomarkers: Pathogenic ATM mutation; hormone receptor-positive; HER2-negative; Oncotype DX score 1/100

As of August 2024, Krista had completed mastectomy/reconstruction surgery and was continuing adjuvant tamoxifen with low reported recurrence risk.

The Patient StoryRead more →

Stage I Invasive Lobular Carcinoma: Jessica's Patient Story

Patient Info: Jessica, Female, 40s | Stage I

Biomarkers: Myriad genetic testing negative; Oncotype DX score 19; RSClin recurrence risk 19%; isolated tumor cells around 1 sentinel lymph node without invasion

As of July 2024, Jessica had completed bilateral mastectomy for Stage IB ILC and was moving forward with radiation and long-term hormone suppression after chemotherapy was not recommended.

Lobular Breast Cancer AllianceRead more →

Triple-positive breast cancer: complete response to targeted therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer; SBDS variants present; no detected TP53 variant on MyeloSeq.

Metastatic Site: liver

Stage IV triple-positive breast cancer with liver metastasis achieved complete response after paclitaxel, trastuzumab, pertuzumab, and G-CSF support; complete response was maintained for 18 months after treatment initiation while on maintenance HER2-directed and endocrine therapy.

PubMed CentralRead more →

Stage IV Breast Cancer: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: Hormone-positive breast cancer; specific receptor details not reported

Metastatic Site: bone: rib, spine, pelvis

As of July 2024, Samantha was living with Stage IV hormone-positive breast cancer with bone metastases. Current treatment was working in most areas, but a breast tumor continued to grow and was surgically removed; ongoing treatment and 3-month scans were reported.

YouTube — The Patient StoryRead more →

HR-positive HER2-negative metastatic breast cancer: bone metastases managed with sequential endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 90%+, PR 80%+, HER2-. CA 15-3 was tracked during treatment.

Metastatic Site: skull base; spine; sternum; ribs; left iliac bone;…

Metastatic HR-positive, HER2-negative breast cancer remained under active management; after earlier progression, palbociclib plus fulvestrant and zoledronic acid produced stable/remission findings on PET/CT at 3 months and again 1 year later, with continued 3-month follow-up recommended.

PubMed CentralRead more →

Stage 4 luminal A breast cancer: tumor regression on hormone therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: skin, soft tissue, lungs

Metastatic Luminal A breast cancer involving skin/soft tissue and lungs showed regressing tumors and stable lung metastasis after 3 months of anti-hormone therapy plus capecitabine; longer-term control was not reported.

PubMed CentralRead more →

Finding A Lump To BREAST CANCER!

Patient Info: Kelsey Harrison, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of July 2024, Kelsey had completed chemotherapy, double mastectomy with axillary lymph-node removal, and radiation, and was continuing tamoxifen plus Lupron ovarian suppression with additional planned systemic therapy.

The Patient StoryRead more →

HER2-positive breast cancer: surgery after neoadjuvant therapy

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER 1% weakly positive; PR-negative; HER2-positive

No evidence of disease on follow-up while taking anastrozole after pathologic complete response to neoadjuvant T-DM1, lumpectomy/SLNB, radiotherapy, and adjuvant trastuzumab for Stage I HER2-positive breast cancer.

PubMed CentralRead more →

Stage II Invasive Lobular Carcinoma: Lizzie's Survivor Story

Patient Info: Lizzie, Female | Stage II

Lizzie completed mastectomy, reconstruction-related surgery and 5 weeks of radiation. She remained on a planned 10-year course of an aromatase inhibitor and became active in breast cancer research advocacy.

Lobular Breast Cancer AllianceRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Liz's Patient Story

Patient Info: Liz O'Riordan, Female, 40s | Stage III

Biomarkers: ER-positive; HER2-negative; PIK3CA mutation reported by patient

As of June 2024, Liz described Stage III ER-positive/HER2-negative mixed ductal and lobular breast cancer followed by 2 locoregional recurrences after mastectomy; no distant metastatic disease was described for her personal story.

YouTube — Dr Liz O'RiordanRead more →

BRCA2-mutant metastatic breast cancer: complete response with rucaparib maintenance

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Germline BRCA2 mutation; somatic BRCA2 mutation; HER2 amplification not seen by FISH; grade III IDC

Metastatic Site: bone

She maintained a complete response for 2 years on rucaparib, letrozole, and zoledronic acid after upfront metastatic BRCA2-mutated breast cancer involving bone, axillary nodes, and right-breast nodules.

PubMed CentralRead more →

Invasive Lobular Carcinoma: Kim's Survivor Story

Patient Info: Kim, Female

Biomarkers: ER 99% positive; PR 85% positive; HER2-negative

Kim’s ER-positive, PR-positive, HER2-negative ILC responded strongly to Zoladex and Letrozole before skin-sparing mastectomy, with 90% tumor necrosis, clear margins, no lymph node spread, and confirmation that she was cancer-free.

Lobular Breast Cancer AllianceRead more →

ER/PR-positive invasive mucinous breast cancer: mastectomy, DIEP reconstruction, and tamoxifen

Patient Info: Anonymized, trans woman, 50s

Biomarkers: ER 100% positive; PR 100% positive; HER2-negative; 19-gene hereditary cancer panel negative

As of May 2024, she was 1 year after bilateral DIEP free-flap reconstruction, satisfied with the cosmetic result, taking tamoxifen for recurrence-risk reduction, and planning nipple reconstruction; no recurrence status beyond the postoperative course was stated.

PubMed CentralRead more →

Stage IV Invasive Lobular Carcinoma: Melissa's Patient Story

Patient Info: Melissa Adams, Female | Stage IV

Melissa’s breast cancer progressed after maintenance hormone therapy and was reassigned as Stage IV. She describes living with incurable disease while focusing on keeping the cancer at bay and staying engaged with family, church, and advocacy.

Stage 4 lobular breast cancer: bone therapy switch to denosumab

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Not reported for breast cancer; CRP 21 mg/dL and ESR 27 mm/hr were elevated during orbital inflammation workup

Metastatic Site: bone

As of April 2024, zoledronate-associated ocular inflammation resolved within 2.5 weeks, vision returned to 20/20 after about 3 weeks, and bone-support treatment was changed to denosumab; breast-cancer response was not reported.

PubMed CentralRead more →

Invasive lobular breast cancer with isolated scalp metastasis: excision and endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Original breast tumor: ER-positive; PR-positive; scalp metastasis: CK7-positive; ER-positive; GCDFP-15 partially positive

Metastatic Site: scalp/skin

As of April 2024, she had no signs of recurrence in the breast or scalp and no distant metastasis after excision of the isolated scalp metastasis while continuing anastrozole.

PubMed CentralRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Allison's Patient Story

Patient Info: Allison Tierney, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; CHEK2 mutation; BRCA1/2 negative

As of March 2024, Allison had completed Taxol and Herceptin treatment, was on tamoxifen planned for 10 years, and had moved to 6-month oncology follow-up. No metastatic disease or recurrence was reported.

YouTube — The Patient StoryRead more →

Metastatic hormone receptor-positive breast cancer with paraneoplastic eosinophilic fasciitis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive; PR-positive; eosinophilia during paraneoplastic eosinophilic fasciitis flare

Metastatic Site: pelvis

As of February 2024, paraneoplastic eosinophilic fasciitis had remitted after prednisone plus systemic breast-cancer therapy, and 6-month follow-up showed no further skin recurrence or cancer progression.

PubMed CentralRead more →

Stage IV BRCA Breast Cancer: Dena's Patient Story

Patient Info: Dena Ofengeim, Under 40 | Stage IV

Biomarkers: Hormone receptor-positive; BRCA mutation

Metastatic Site: spine

Dena improved rapidly after treatment, regained her mobility, returned to an active life, and remained on therapy for metastatic breast cancer.

Dana-FarberRead more →

Invasive Lobular Carcinoma: Sally's Survivor Story

Patient Info: Sally Johnston, 70+

Biomarkers: Estrogen receptor-positive

Sally was in remission by the end of 2014 and remained active about 10 years after treatment.

Dana-FarberRead more →

Aggressive breast cancer presenting with severe skin infection

Patient Info: Anonymized, Female

Biomarkers: ER 99% positive; PR 99% positive; HER2 1+ / negative; Ki-67 3%; grade 2; 3 interpectoral lymph nodes negative; later axillary-node biopsy benign

She recovered from sepsis and surgery, had no distant metastases and a benign axillary-node biopsy, and was receiving adjuvant radiation with anastrozole ongoing.

PubMed CentralRead more →

Stage III Breast Cancer: Gail's Patient Story

Patient Info: Gail, Female, 60s | Stage III

Biomarkers: Luminal A

As of 2024, Gail had Stage III luminal A breast cancer and was awaiting the start of planned treatment with lumpectomy, radiation therapy, chemotherapy, and hormone therapy.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Paula's Patient Story

Patient Info: Paula | Stage II

Paula was receiving chemotherapy and hormonal therapy for stage 2 breast cancer, with additional treatments included in the recommended plan.

Our Cancer StoriesRead more →